Lyft Names Longtime Executive Michael Brous as New CFO After Erin Brewer Retires
Analysts remain cautious on scale.
Already have an account? Sign in.
Analysts remain cautious on scale.
Open-label Part C data showed extra MADRS improvement and ~30% remission after another 25 mg dose. Safety was unchanged. Launch targeted for H1 2027.
Analysts see a likely PFS win in HARMONi-3 later in 2026.
Confirmed responses fell from 46% (n=13) to 36% (12/33). Data beat old 2L chemo rates, yet safety, distant catalysts and financing overhang hit the stock.